## **National Board of Examinations**

Question Paper Name :	DrNB CLINICAL HAEMATOLOGY Paper2
Subject Name :	DrNB CLINICAL HAEMATOLOGY Paper2
Creation Date :	2022-12-22 19:37:48
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

## **DrNB CLINICAL HAEMATOLOGY Paper2**

**Group Number:** 1 Group Id: 3271871891 **Group Maximum Duration:** 0 **Group Minimum Duration:** 180 **Show Attended Group?:** No **Edit Attended Group?:** No 100 **Group Marks:** Is this Group for Examiner?: No **Examiner permission: Cant View Show Progress Bar?:** No

## **DrNB CLINICAL HAEMATOLOGY Paper2**

**Section Id:** 3271871894

Section Number: 1

Section type: Offline

Mandatory or Optional: Mandatory

Number of Questions to be attempted: 10

Section Marks: 100

**Enable Mark as Answered Mark for Review and** 

**Clear Response:** 

Yes

**Maximum Instruction Time:** 0

Sub-Section Number: 1

**Sub-Section Id:** 3271871898

**Question Shuffling Allowed:** No

Is Section Default?: null

Question Number: 1 Question Id: 32718718522 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time:0

**Correct Marks: 10** 

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

- 1. Red blood cell transfusion:
- a) Discuss the pretransfusion compatibility testing strategies for red cell transfusion. [4]
- b) What are the recommendations for pretransfusion compatibility testing for emergency blood release when no time is available for detailed testing. [3]
- c) Describe the potential confounders of the results for the pretransfusion compatibility testing. [3]

Question Number: 2 Question Id: 32718718523 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

A 33-year-old male (Blood Group: A-positive) is planned for matched sibling donor transplant with a 38-year-old multiparous sister (Blood Group: B-positive) for AML in CR1. Please discuss the following about this patient:

- a) Component transfusion strategies pre- and post-engraftment in this patient. [4]
- b) Explain the requirement of graft manipulation (if any) with a scientific basis. [3]
- c) Incidence of Post-transplant PRCA in this patient and its management (if it develops). [3]

Question Number: 3 Question Id: 32718718524 Question Type: SUBJECTIVE Consider As Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

A 21-year-old lady developed pancytopenia, and during evaluation, her bone marrow examination was suggestive of Hemophagocytic Lymphohistiocytosis (HLH):

- a) Overview of initial management and monitoring. [4]
- b) During the initial evaluation of HLH, how important is genetics in this patient. [3]
- c) How to treat relapse or refractory disease? [3]

Question Number : 4 Question Id : 32718718525 Question Type : SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

A 62-year-old male complained of bone pains, easy fatigability, and hip fracture after trivial trauma:

- a) What are the hematological and non-hematological causes of this symptom complex? [5]
- b) Describe the algorithmic approach for this patient. [5]

Question Number: 5 Question Id: 32718718526 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

A 66-year-old male, during a pre-operative check-up for cataract surgery, was found to have lymphocytosis (88%). Peripheral blood smear revealed smudge cells and mature-looking

lymphocytes:

a) Kindly suggest evaluation for risk stratification in this case and appropriate prognosis about

disease progression and survival outcomes based on risk stratification. [4]

b) Enumerate the targeted therapies available in our country for this disorder. [3]

c) Enumerate the toxicities of the targeted therapies and discuss the management of these

toxicities in this patient. [3]

Question Number: 6 Question Id: 32718718527 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

A 52-year-old post-menopausal female was found to have generalized lymphadenopathy with

hepatosplenomegaly. There was a suspicion of Mantle cell lymphoma (MCL) as reported from a

peripheral center. Discuss the following:

a) Diagnostic challenges in MCL. [4]

b) Frontline management of MCL with special attention to the Indian perspective. [3]

c) Role of novel agents in the management of MCL. [3]

Question Number: 7 Question Id: 32718718528 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

A 55-year-old female presented to the medical OPD with anasarca. The evaluation revealed

hypoalbuminemia with gross proteinuria (6g/day). A kidney biopsy revealed amorphous material

with apple-green birefringence:

a) What can be the other clinical manifestations of the disease with which the patient is suffering?

[3]

b) What further evaluation would you advise for this patient? [4]

c) Role of transplantation in this patient and what special precautions would you take in this

patient? [3]

Question Number: 8 Question Id: 32718718529 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Neutrophils are the primary defense of the body, and abnormalities in the neutrophil function

(Neutrophil dysfunction disorders) can make an individual prone to infections:

a) Enumerate the causes/types of Neutrophil dysfunction disorders. [4]

b) How do these patients present, and what are the indications for evaluation. [4]

c) Brief note on the Neutrophil function testing. [2]

Question Number: 9 Question Id: 32718718530 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

A 58-year-old male presented with a high-stepping gait and lower limb weakness. During the evaluation, he was found to have monoclonal gammopathy but did not fulfill the criteria for

Multiple myeloma:

a) Describe the various neurological manifestations of monoclonal gammopathies. [5]

b) Classify and mention the diagnostic criteria for monoclonal gammopathies which do not meet

the IMWG Criteria for Overt Multiple Myeloma. [5]

Question Number: 10 Question Id: 32718718531 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Describe the following regarding platelet transfusion:

a) Indications. [2]

b) Donor issues. [2]

c) Processing/storage. [2]

d) Determining response. [2]

e) Complications. [2]